Literature DB >> 23713767

Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects.

Jorg Taubel1, Georg Ferber, Ulrike Lorch, Velislav Batchvarov, Irina Savelieva, A John Camm.   

Abstract

AIMS: The aims of this study were three-fold and were to (i) investigate the effect of food (fasted and fed state) on the degree of QT prolongation caused by moxifloxacin under the rigorous conditions of a TQT study, (ii) differentiate the effects on QTc that arise from changes in PK from those arising as a result of electrophysiological changes attributable to raised levels of C-peptide [11] offsetting in part the IKr blocking properties of moxifloxacin and (iii) characterize the QTc F profile of oral moxifloxacin (400 mg) in healthy Japanese volunteers compared with Caucasian subjects.
METHODS: The study population consisted of 32 healthy non-smoking, Caucasian (n = 13) and Japanese (n = 19), male and female subjects, aged between 20-45 years with a body mass index of between 18 to 25 kg m(-2). Female volunteers were required to use an effective contraceptive method or be abstinent. Subjects with ECGs which were deemed unsuitable for evaluation in a TQT study were excluded. ECGs were recorded in triplicate with subsequent blinded manual adjudication of the automated interval measurements. Electrocardiograms in the placebo arm were recorded twice in fasted and fed condition.
RESULTS: The results demonstrated a substantial change in the typical moxifloxacin effect on the ECG. The effect on ΔΔQTc in the fed state led to a significant delay and a modest reduction compared with the fasted state correcting both conditions with the corresponding placebo data. The largest QTc F change from baseline in the fed state was observed at 4 h with a peak value of 11.6 ms (two-sided 90% CI 9.1, 14.1). In comparison, the largest QTc F change observed in the fasted state was 14.4 ms (90% CI 11.9, 16.8) and occurred at 2.5 h post-dose. The PK of moxifloxacin were altered by food and this change was consistent with the observed QTc F change. In the fed state plasma concentrations of moxifloxacin were considerably and consistently lower in comparison with the fasted state, and this applied to both ethnicities. The concentration-effect analysis revealed that there was no change in slope and confirmed that the difference in this analysis was caused by a change in the PK profile of moxifloxacin. Comparisons of the moxifloxacin effect in the fed state compared with fasted placebo also revealed a pharmacodynamic effect whereby a meal appears to antagonize the effects of moxifloxacin on the lengths of the QTc interval.
CONCLUSIONS: Our findings demonstrate that the food effect by itself leads to a shortening of the QTc interval offsetting in part the effects of a 400 mg single dose of oral moxifloxacin. The typical moxifloxacin PK profile is also altered by food prior to dosing reducing the Cmax and delays the peak effects on QTc up to several hours thereby reducing the overall magnitude of the effect and delaying the peak QTc prolongation. The contribution of the two effects was clearly discernible. Given that moxifloxacin is sometimes given with food in TQT studies, consideration should be given to adequate baseline corrections and appropriate sampling time points. In this study the PK-PD relationship was similar for Japanese and Caucasian subjects in the fed and fasted conditions, thereby providing further evidence that the sensitivity to the QTc prolonging effects of fluoroquinolones was likely to be independent of ethnicity. The small differences observed between the two subpopulations were not statistically significant. However, future studies should give consideration to formal ethnic comparisons as a secondary outcome parameter as very little is known about the relationship between ethnicity and drug effects on cardiac repolarization.
© 2013 The British Pharmacological Society.

Entities:  

Keywords:  Japanese bridging; PK/PD; QTc prolongation; fed and fasted moxifloxacin; thorough QT study

Mesh:

Substances:

Year:  2014        PMID: 23713767      PMCID: PMC3895358          DOI: 10.1111/bcp.12168

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers.

Authors:  J Lettieri; R Vargas; V Agarwal; P Liu
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 2.  Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter?

Authors:  Rashmi R Shah
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

3.  Profile of moxifloxacin drug interactions.

Authors:  H Stass; D Kubitza
Journal:  Clin Infect Dis       Date:  2001-03-15       Impact factor: 9.079

4.  Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin.

Authors:  K S Yu; J Y Cho; J H Shon; K S Bae; S Y Yi; H S Lim; I J Jang; S G Shin
Journal:  Clin Pharmacol Ther       Date:  2001-09       Impact factor: 6.875

5.  Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.

Authors:  J Kang; L Wang; X L Chen; D J Triggle; D Rampe
Journal:  Mol Pharmacol       Date:  2001-01       Impact factor: 4.436

6.  The effect of moxifloxacin on QTc and implications for the design of thorough QT studies.

Authors:  D M Bloomfield; J T Kost; K Ghosh; D Hreniuk; L A Hickey; M J Guitierrez; K Gottesdiener; J A Wagner
Journal:  Clin Pharmacol Ther       Date:  2008-10       Impact factor: 6.875

7.  Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects.

Authors:  Ruth Dixon; Sarah Job; Ruth Oliver; Debra Tompson; John G Wright; Kay Maltby; Ulrike Lorch; Jorg Taubel
Journal:  Br J Clin Pharmacol       Date:  2008-07-23       Impact factor: 4.335

8.  Electrocardiographic QTc changes due to moxifloxacin infusion.

Authors:  Marek Malik; Katerina Hnatkova; Anna Schmidt; Peter Smetana
Journal:  J Clin Pharmacol       Date:  2009-06       Impact factor: 3.126

9.  Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation.

Authors:  Dagmar Kubitza; Wolfgang Mueck; Michael Becka
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

10.  Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval.

Authors:  M Iwamoto; J T Kost; G C Mistry; L A Wenning; S A Breidinger; T C Marbury; J A Stone; K M Gottesdiener; D M Bloomfield; J A Wagner
Journal:  J Clin Pharmacol       Date:  2008-04-25       Impact factor: 3.126

View more
  22 in total

1.  Comparison of Digital 12-Lead ECG and Digital 12-Lead Holter ECG Recordings in Healthy Male Subjects: Results from a Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.

Authors:  Duolao Wang; Ameet Bakhai; Radivoj Arezina; Jörg Täubel
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-03-28       Impact factor: 1.468

2.  Stability of the Effect of a Standardized Meal on QTc.

Authors:  Jörg Täubel; Sara Fernandes; Georg Ferber
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-05-28       Impact factor: 1.468

Review 3.  Precision medicine: does ethnicity information complement genotype-based prescribing decisions?

Authors:  Rashmi R Shah; Andrea Gaedigk
Journal:  Ther Adv Drug Saf       Date:  2017-12-01

4.  Establishing assay sensitivity in QT studies: experience with the use of moxifloxacin in an early phase clinical pharmacology study and comparison with its effect in a thorough QT study.

Authors:  Rashmi R Shah; Pierre Maison-Blanche; Thierry Duvauchelle; Philippe Robert; Emmanuel Denis
Journal:  Eur J Clin Pharmacol       Date:  2015-10-01       Impact factor: 2.953

5.  Moxifloxacin-induced QTc interval prolongations in healthy male Japanese and Caucasian volunteers: a direct comparison in a thorough QT study.

Authors:  Joel Morganroth; Yaning Wang; Michael Thorn; Yuji Kumagai; Stuart Harris; Norman Stockbridge; Robert Kleiman; Rashmi Shah
Journal:  Br J Clin Pharmacol       Date:  2015-07-02       Impact factor: 4.335

6.  Analysis of Respiratory Fluoroquinolones and the Risk of Sudden Cardiac Death Among Patients Receiving Hemodialysis.

Authors:  Magdalene M Assimon; Patrick H Pun; Lily Chin-Hua Wang; Sana M Al-Khatib; M Alan Brookhart; David J Weber; Wolfgang C Winkelmayer; Jennifer E Flythe
Journal:  JAMA Cardiol       Date:  2022-01-01       Impact factor: 30.154

7.  Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin.

Authors:  Nikunjkumar Patel; Oliver Hatley; Alexander Berg; Klaus Romero; Barbara Wisniowska; Debra Hanna; David Hermann; Sebastian Polak
Journal:  AAPS J       Date:  2018-03-14       Impact factor: 4.009

8.  A thorough QT study to assess the effects of tbo-filgrastim on cardiac repolarization in healthy subjects.

Authors:  Liat Adar; Noa Avisar; Andreas Lammerich; Robert B Kleiman; Ofer Spiegelstein
Journal:  Drug Des Devel Ther       Date:  2015-05-15       Impact factor: 4.162

Review 9.  Pharmacogenetics of Drug-Induced QT Interval Prolongation: An Update.

Authors:  Maartje N Niemeijer; Marten E van den Berg; Mark Eijgelsheim; Peter R Rijnbeek; Bruno H Stricker
Journal:  Drug Saf       Date:  2015-10       Impact factor: 5.606

10.  A Computational Pipeline to Predict Cardiotoxicity: From the Atom to the Rhythm.

Authors:  Pei-Chi Yang; Kevin R DeMarco; Parya Aghasafari; Mao-Tsuen Jeng; John R D Dawson; Slava Bekker; Sergei Y Noskov; Vladimir Yarov-Yarovoy; Igor Vorobyov; Colleen E Clancy
Journal:  Circ Res       Date:  2020-02-24       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.